Takeda Pharmaceutical (TAK) Earnings Date, Estimates & Call Transcripts $14.67 -0.17 (-1.15%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$14.68 +0.02 (+0.10%) As of 07/11/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Takeda Pharmaceutical Earnings Summary Takeda Pharmaceutical posted Q4 2025 earnings on May 8, 2025, reporting an EPS of $0.16, which missed analysts' consensus estimates of $0.24 by $0.08. Quarterly revenue was reported to be $7.34 billion, below the consensus estimate of $8.02 billion. With a trailing EPS of $0.22 and a P/E Ratio of 66.68, Takeda Pharmaceutical's earnings are expected to grow 0.61% next year, from $1.64 to $1.65 per share. Upcoming Q1 Earnings DateJul. 30Before Market OpensEstimatedConsensus EPS (May. 8) $0.24 Actual EPS (May. 8) $0.16 Missed By -$0.08 Actual Revenue (May. 8) $7.34BQ4 2025 Earnings ResourcesQ4 2025 Earnings ReportConference Call Transcript & Audio Interim Report Slide Deck Annual Report (20-F)TAK Upcoming EarningsTakeda Pharmaceutical's Q1 2026 earnings is scheduled for Wednesday, July 30, 2025, with a conference call scheduled at 6:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2026 Earnings ReportSlide DeckFull Screen Slide DeckPowered by Get Takeda Pharmaceutical Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Takeda Pharmaceutical and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataTAK Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.TAK Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Takeda Pharmaceutical Analyst EPS EstimatesCurrent Year EPS Consensus Estimate $1.64 EPSNext Year EPS Consensus Estimate $1.65 EPS Takeda Pharmaceutical Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 7/30/2025(Estimated)-------5/8/2025Q4 2025$0.24$0.16 -$0.08-$0.21$8.02B$7.34B1/30/2025Q3 2025$0.34$0.42+$0.08$0.05--7/31/2024Q1 2025$0.37$0.56+$0.19$0.93-$7.75B2/1/2024Q3 2024-$0.51-$0.79-$7.52B10/26/2023Q2 2024-$0.50-$0.86-$6.94B7/27/2023Q1 2024-$0.55-$0.89-$7.71B Takeda Pharmaceutical Earnings - Frequently Asked Questions When is Takeda Pharmaceutical's earnings date? Takeda Pharmaceutical has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, July 30th, 2025 based off last year's report dates. Learn more on TAK's earnings history. What guidance has Takeda Pharmaceutical issued on next quarter's earnings? Takeda Pharmaceutical updated its FY 2025 earnings guidance on Thursday, May, 8th. The company provided earnings per share guidance of 3.180-3.180 for the period. The company issued revenue guidance of $29.7 billion-$29.7 billion. Did Takeda Pharmaceutical beat their earnings estimates last quarter? In the previous quarter, Takeda Pharmaceutical (NYSE:TAK) missed the analysts' consensus estimate of $0.24 by $0.08 with a reported earnings per share (EPS) of $0.16. Learn more on analysts' earnings estimate vs. TAK's actual earnings. How can I listen to Takeda Pharmaceutical's earnings conference call? The conference call for Takeda Pharmaceutical's latest earnings report can be listened to online. Listen to Conference Call How can I read Takeda Pharmaceutical's conference call transcript? The conference call transcript for Takeda Pharmaceutical's latest earnings report can be read online. Read Transcript How much revenue does Takeda Pharmaceutical generate each year? Takeda Pharmaceutical (NYSE:TAK) has a recorded annual revenue of $4.58 trillion. How much profit does Takeda Pharmaceutical generate each year? Takeda Pharmaceutical (NYSE:TAK) has a recorded net income of $712.33 million. TAK has generated $0.22 earnings per share over the last four quarters. What is Takeda Pharmaceutical's price-to-earnings ratio? Takeda Pharmaceutical (NYSE:TAK) has a trailing price-to-earnings ratio of 66.68 and a forward price-to-earnings ratio of 8.95. What is Takeda Pharmaceutical's EPS forecast for next year? Takeda Pharmaceutical's earnings are expected to grow from $1.64 per share to $1.65 per share in the next year, which is a 0.61% increase. More Earnings Resources from MarketBeat Related Companies Sanofi Earnings Results GSK Earnings Results argenex Earnings Results BioNTech Earnings Results BeOne Medicines Earnings Results Teva Pharmaceutical Industries Earnings Results Insmed Earnings Results Summit Therapeutics Earnings Results Intra-Cellular Therapies Earnings Results Genmab A/S Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s Next This page (NYSE:TAK) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Takeda Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
